DNA fragments of altered electrophoretic mobility in leukemia samples can arise from double-strand DNA breaks at nuclease hypersensitive sites of active genes
dc.contributor.author | Miesfeldt, Susan | en_US |
dc.contributor.author | Kim, Suil | en_US |
dc.contributor.author | Hanson, Curtis A. | en_US |
dc.contributor.author | Bohjanen, Paul R. | en_US |
dc.contributor.author | Leiden, Jeffrey M. | en_US |
dc.contributor.author | Crist, William M. | en_US |
dc.contributor.author | Carroll, Andrew J. | en_US |
dc.contributor.author | Thompson, Craig B. | en_US |
dc.date.accessioned | 2006-04-10T15:40:51Z | |
dc.date.available | 2006-04-10T15:40:51Z | |
dc.date.issued | 1993-07-01 | en_US |
dc.identifier.citation | Miesfeldt, Susan, Kim, Suil, Hanson, Curtis A., Bohjanen, Paul R., Leiden, Jeffrey M., Crist, William M., Carroll, Andrew J., Thompson, Craig B. (1993/07/01)."DNA fragments of altered electrophoretic mobility in leukemia samples can arise from double-strand DNA breaks at nuclease hypersensitive sites of active genes." Cancer Genetics and Cytogenetics 68(1): 34-41. <http://hdl.handle.net/2027.42/30693> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T53-47PYB6D-32/2/f76585a273cfa755798e641aeddf0bea | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/30693 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8330281&dopt=citation | en_US |
dc.description.abstract | Chromosome translocations that disrupt or alter gene function have been implicated in the pathogenesis of a variety of malignancies. Therefore, identification of a translocation breakpoint has become a more important means by which to identify genes involved in cellular transformation. A common site of translocation in myeloid and lymphoid malignancies involves 11q23. One human protooncogene, ETS1, has been localized to this chromosomal segment, and several tumors with 11q23 translocations have been shown to have altered ETS1 DNA migration after restriction enzyme digestion. Two laboratories, however, have recently localized the 11q23 breakpoint region to a small region of DNA telomeric of the CD3 loci, a region at considerable distance from the ETS1 gene locus. Therefore, it is difficult to reconcile the studies that suggest altered migration of fragments associated with ETS1 and lack of a localization of the breakpoint to a region near the ETS1 gene. Recently, in our studies to characterize the promoter/enhancer region of the ETS1 protooncogene, we had the opportunity to analyze DNA from 18 patients with acute leukemia involving chromosome 11q23 aberrations. We were unable to demonstrate rearrangement of the ETS1 gene in this group, thus confirming that the 11q23 breakpoint does not involve ETS1 protooncogene. In one patient, however, a DNA break in the region of the ETS1 promoter was detected reproducibly. This DNA break was mapped to the major DNaseI hypersensitive site in the ETS1 promoter. Mapping from both sides of the break demonstrated that the break must have occurred during processing of the leukemic cells for DNA analysis. Therefore, artifactual DNA breaks can occur at nuclease-hypersensitive sites of active genes. These data suggest that previous reports of chromosomal translocations involving the ETS1 protooncogene may have resulted from DNA breaks at nuclease hypersensitive sites. This mechanism may account for sporadic case reports of altered restriction enzyme fragment migration involving genes that are not ultimately shown to be associated with the chromosome translocation being examined. | en_US |
dc.format.extent | 715462 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | DNA fragments of altered electrophoretic mobility in leukemia samples can arise from double-strand DNA breaks at nuclease hypersensitive sites of active genes | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Molecular and Cell Biology Program, University of Michigan Medical Center, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan Medical Center, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Microbiology and Immunology, University of Michigan Medical Center, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Howard Hughes Medical Institute, USA | en_US |
dc.contributor.affiliationother | Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennesse, USA | en_US |
dc.contributor.affiliationother | Department of Pediatrics, University of Tennessee, Memphis College of Medicine, USA | en_US |
dc.contributor.affiliationother | Laboratory of Medical Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA | en_US |
dc.contributor.affiliationother | Pediatric Oncology Group, St. Louis, Missouri, USA | en_US |
dc.identifier.pmid | 8330281 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/30693/1/0000338.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0165-4608(93)90071-S | en_US |
dc.identifier.source | Cancer Genetics and Cytogenetics | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.